ImportRefusal LogoImportRefusal

Violation Code: 237

FDA Violation

Charge Code: NO PMA

3,842
Total Refusals
1657
Affected Firms
1/22/2026
Latest Case
10/12/2001
First Case

Violation Details

Violation Code (ASC ID)
237
Charge Code
NO PMA
Description
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the device appears to be a Class III device and does not appear to have in effect an approved application for premarket approval pursuant to Section 515 of the Act, or an exemption pursuant to Section 520(g)(1).
Legal Section
501(f)(1)(B), 801(a)(3); ADULTERATION

Most Affected Firms

#Firm NameLocationCases
1Q-Med ABUppsala, SWEDEN109
2Admedes GmbHPforzheim, GERMANY104
3Medtronic Puerto Rico Operations Co.Humacao, UNITED STA69
4Allergan Industrie SASPringy, FRANCE61
5Medtronic IncMounds View, UNITED STA52
6Medtronic Sofamor Danek USA, IncMemphis, UNITED STA51
7E-FILLERS SAAthens, GREECE49
8Warsaw Orthopedic, Inc.Warsaw, UNITED STA46
9Bodyjewellleryshop LtdWatford, UNITED KIN45
10Edwards Lifesciences AgRio Haina, DOMINICAN 44
11Edwards LifesciencesBajos De Haina, DOMINICAN 39
12Danamedic ApsKgs. Lyngby, DENMARK39
13DreamCon Co. Ltd.Yangsan, SOUTH KORE34
14Tae-Chang Industrial Co., Ltd.Gumi, SOUTH KORE32
15Ultramax Products LtdWakefield, UNITED KIN32
16Micro Therapeutics, Inc.Irvine, UNITED STA31
17X4 Labs Inc.Montreal, CANADA29
18Cs Innovation PteSin, SINGAPORE25
19Mystim GmbhMombris, GERMANY23
20Interojo Inc.Pyeongtaek City, SOUTH KORE22

Recent Import Refusals

DateProductFirm
1/22/2026
LENS, INTRAOCULAR
86HQL
1/21/2026
LENS, CONTACT, FOR READING DISCOMFORT
86NIC
RESHIP.COMUNITED KIN
1/21/2026
LENS, CONTACT (OTHER MATERIAL) - DAILY
86HQD
1/21/2026
IMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE
79LMH
VASYL KUTSPORTUGAL
1/21/2026
IMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE
79LMH
METHODOLOGYSOUTH KORE
1/21/2026
IMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE
79LMH
AbbVie Inc.UNITED STA
1/21/2026
IMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE
79LMH
Across Co., LtdSOUTH KORE
1/20/2026
IMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE
79LMH
Exocobio, Inc.SOUTH KORE
1/20/2026
IMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE
79LMH
1/20/2026
OTHER HAIR PREPARATIONS, NON-COLORING), N.E.C.
53EL99
1/20/2026
OTHER SKIN CARE PREPARATIONS, N.E.C.
53LY99
1/20/2026
OTHER SKIN CARE PREPARATIONS, N.E.C.
53LY99
1/20/2026
EYELASH CLEANSERS (EYE MAKEUP PREPARATIONS)
53CL15
1/20/2026
IMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE
79LMH
AllerganUNITED STA
1/12/2026
COLLAGEN (COSMETIC RAW MATERIAL)
53PD02

Frequently Asked Questions

What is FDA violation code 237?

237 is an FDA violation code that indicates: "The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the device appears to be a Class III device and does not appear to have in effect an approved application for premarket approval pursuant to Section 515 of the Act, or an exemption pursuant to Section 520(g)(1).". This violation is based on 501(f)(1)(B), 801(a)(3); ADULTERATION of the Federal Food, Drug, and Cosmetic Act.

How many import refusals have been issued for violation 237?

According to FDA Import Refusal data, there have been 3842 import refusals issued for violation code 237, affecting 1657 unique firms.

When was the most recent refusal for violation 237?

The most recent import refusal for violation 237 was on January 22, 2026.

What products are commonly refused for violation 237?

Products commonly refused under violation 237 include: LENS, INTRAOCULAR, LENS, CONTACT, FOR READING DISCOMFORT, LENS, CONTACT (OTHER MATERIAL) - DAILY, IMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE. These products were refused entry because they did not meet FDA requirements.

What is the legal basis for FDA violation code 237?

Violation code 237 is based on 501(f)(1)(B), 801(a)(3); ADULTERATION of the Federal Food, Drug, and Cosmetic Act (FD&C Act). This section of the law establishes requirements that imported products must meet to be allowed entry into the United States.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.